尿酸冠狀動脈鈣化 / Uric Acid Coronary Calcification

SKU Rehab0084
HK$3,080.00
In stock
1
Product Details

如你有此疾病,請遵照閣下醫生的完整醫療方案;而是否使用多學科復康方案前,你必須咨詢主診醫生的意見,如果閣下的主診醫生不建議您加入補充劑調理組合,請你不要使用。如果你需要尋求其他醫生作第二咨詢,閣下可聯絡我們線上<無邊界醫生>或你自己城市內的其他專業醫生的再診斷。

探討無症狀高尿酸血症患者尿酸單鈉(MSU)晶體沉積與冠心病(CAD)嚴重程度及範圍的關係。

方法: 在這項橫斷面研究中,入選了連續住院的非ST段抬高急性冠狀動脈事件和無症狀高尿酸血症(血清尿酸濃度≥7.0 mg/dl)或正常血尿酸(血清尿酸濃度<7.0 mg/dl)患者。在無症狀高尿酸血症患者中,通過超聲評估雙膝和第一跖趾關節以及補償偏振光顯微鏡來確定MSU晶體的存在。冠心病通過冠狀動脈造影進行評估,並考慮以下變數:1)中度至重度冠狀動脈鈣化的存在,2)顯著冠狀動脈狹窄的數量,以及3)多支血管疾病的存在。多元回歸分析表明冠心病嚴重程度的變數與MSU晶體的存在之間的關聯。

結果: 140名患者入選。在進行超聲和顯微鏡分析後,將患者分為正常尿毒癥(n = 66)、無症狀高尿酸血症(n = 61)和無症狀高尿酸血症伴MSU晶體(n = 13)。無症狀高尿酸血症伴MSU晶體的患者中,中度至重度冠狀動脈鈣化的患病率顯著高於無症狀高尿酸血症單獨患者和正常尿酸血症患者(P = 0.003)。觀察到中度至重度鈣化與無症狀高尿酸血症伴晶體之間存在獨立相關性(比值比16.8,P = 0.002)。其他變數無顯著相關性。

結論: 無症狀高尿酸血症患者無症狀的MSU晶體沉積與更嚴重的冠狀動脈鈣化有關,提示與晶體沉積相關的更嚴重的CAD。


尿酸冠狀動脈鈣化-多學科研證復康方案

  • 藥物及其他醫療方案,請遵醫從醫生建議
  • 飲食營養請依營養師指引
  • 運動及或心理輔導,請參考各專家建議
  • 為免錯誤診斷及漏診,請上傳最近一個月醫院的專業診斷報告,如證實是此症,則可參加試用期不如意退款計劃#。

可能適合的補充劑支援:

標準組合:

  • 試用時期: 4星期

# <試用期不如意退款計劃>,請參考相關文件

本產品並非根據《藥劑業及毒藥條例》或《中醫藥條例》注册。任何對其提出的索賠均不受此類登記評估的約束。本產品不用於診斷、治療或預防任何疾病。

If you have this disease, please follow your doctor's complete medical plan. You must consult the attending doctor before using the multidisciplinary rehabilitation plan. If your attending doctor does not recommend you to join the supplement conditioning combination, please do not use it. If you need to seek second opinion from other doctors, you can contact our online "Doctors Without Borders", or another professional doctor in your own city.

Uric Acid Coronary Calcification

Abstract

Objective

To evaluate the association between monosodium urate (MSU) crystal deposits in patients with asymptomatic hyperuricemia and the severity and extension of coronary artery disease (CAD).

Methods

In this cross‐sectional study, consecutive inpatients with a non–ST elevation acute coronary event and asymptomatic hyperuricemia (serum uric acid concentration of ≥7.0 mg/dl) or normouricemia (serum uric acid concentration of <7.0 mg/dl) were enrolled. In patients with asymptomatic hyperuricemia, the presence of MSU crystals was determined by ultrasound evaluation of both knees and first metatarsophalangeal joints and by compensated polarized light microscopy. CAD was assessed by coronary angiography, and the following variables were considered: 1) the presence of moderate‐to‐severe coronary artery calcification, 2) the number of significant coronary stenoses, and 3) the presence of multivessel disease. The association between variables indicating the severity of CAD and the presence of MSU crystals was analyzed by multivariate regression.

Results

One hundred forty patients were enrolled. After ultrasonography and microscopic analyses were performed, the patients were classified as having normouricemia (n = 66), asymptomatic hyperuricemia alone (n = 61), and asymptomatic hyperuricemia with MSU crystals (n = 13). The prevalence of moderate‐to‐severe coronary calcification was significantly higher in the patients with asymptomatic hyperuricemia with MSU crystals compared with patients with asymptomatic hyperuricemia alone and patients with normouricemia (P = 0.003). An independent association was observed between the presence of moderate‐to‐severe calcification and asymptomatic hyperuricemia with crystals (odds ratio 16.8, P = 0.002). No significant association was observed for the other variables.

Conclusion

Silent deposition of MSU crystals in patients with asymptomatic hyperuricemia was associated with more severe coronary calcification, which suggests more severe CAD in relation to crystal deposition.

Multidisciplinary research and rehabilitation program for Uric Acid Coronary Calcification
  • Please follow the doctor's advice for drugs and other medical plans
  • Please follow the guidance of nutritionist
  • For sports or psychological counseling, please refer to the experts' suggestions
  • In order to avoid misdiagnosis and missed diagnosis, please upload the professional diagnosis report of the hospital in the latest month. If it is confirmed to be this disease, you can participate in the .#

Possible supplements supporting:

Standard combination:

Trial period: 4 weeks

# Please refer to the relevant documents for the

Products are not registered under the Pharmacy and Poisons Ordinance or the Chinese Medicine Ordinance. Any claim made for it has not been subject to evaluation for such registration. This product is not intended to diagnose, treat or prevent any disease.

Save this product for later